{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:38:48Z","timestamp":1776692328868,"version":"3.51.2"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:00:00Z","timestamp":1585353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:00:00Z","timestamp":1585353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11899-020-00569-2","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T10:02:42Z","timestamp":1585389762000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects"],"prefix":"10.1007","volume":"15","author":[{"given":"Shivani","family":"Seth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linh","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,28]]},"reference":[{"key":"569_CR1","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","volume":"128","author":"MV Dhodapkar","year":"2016","unstructured":"Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016;128:2599\u2013606.","journal-title":"Blood"},{"key":"569_CR2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","volume":"64","author":"RA Kyle","year":"1978","unstructured":"Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978;64:814\u201326.","journal-title":"Am J Med"},{"key":"569_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.4065\/79.7.859","volume":"79","author":"RA Kyle","year":"2004","unstructured":"\u2022\u2022 Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc. 2004;79:859\u201366. Seminal paper demonstrating the characteristics of MGUS.","journal-title":"Mayo Clin Proc"},{"key":"569_CR4","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1038\/bcj.2017.97","volume":"7","author":"O Landgren","year":"2017","unstructured":"Landgren O, Graubard BI, Kumar S, et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J. 2017;7:e618.","journal-title":"Blood Cancer J"},{"key":"569_CR5","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412\u20137.","journal-title":"Blood"},{"key":"569_CR6","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113:5418\u201322.","journal-title":"Blood"},{"key":"569_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241\u20139.","journal-title":"N Engl J Med"},{"key":"569_CR8","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362\u20139.","journal-title":"N Engl J Med"},{"key":"569_CR9","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood.2019846782","volume":"133","author":"TH Mouhieddine","year":"2019","unstructured":"Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal gammopathy of undetermined significance. Blood. 2019;133:2484\u201394.","journal-title":"Blood"},{"key":"569_CR10","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.mayocp.2012.06.014","volume":"87","author":"TM Therneau","year":"2012","unstructured":"Therneau TM, Kyle RA, Melton LJ, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012;87:1071\u20139.","journal-title":"Mayo Clin Proc"},{"key":"569_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","volume":"114","author":"CM Vachon","year":"2009","unstructured":"Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114:785\u201390.","journal-title":"Blood"},{"key":"569_CR12","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Hoppin JA, Beane Freeman LE, Cerhan JR, Katzmann JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113:6386\u201391.","journal-title":"Blood"},{"key":"569_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","volume":"116","author":"O Landgren","year":"2010","unstructured":"Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, et al. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood. 2010;116:1056\u20139.","journal-title":"Blood"},{"key":"569_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1365-2141.2009.07807.x","volume":"147","author":"J Bird","year":"2009","unstructured":"Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147:22\u201342.","journal-title":"Br J Haematol"},{"key":"569_CR15","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"\u2022\u2022 Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348. Current IMWG diagnostic criteria for multiple myeloma.","journal-title":"Lancet Oncol"},{"key":"569_CR16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","volume":"375","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet Lond Engl. 2010;375:1721\u20138.","journal-title":"Lancet Lond Engl"},{"key":"569_CR17","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1182\/blood.V114.22.4883.4883","volume":"114","author":"LM Doyle","year":"2009","unstructured":"Doyle LM, Gundrum JD, Farnen JP, et al. Determining why and which clinicians order serum protein electrophoresis (SPEP), subsequent diagnoses based on indications, and clinical significance of routine follow-up: a study of patients with monoclonal gammopathy of undetermined significance (MGUS). Blood. 2009;114:4883.","journal-title":"Blood"},{"key":"569_CR18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"\u2022\u2022 Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121\u20137. IMWG consensus statement on monitoring asymptomatic monoclonal gammopathies.","journal-title":"Leukemia"},{"key":"569_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3949\/ccjm.86a.17133","volume":"86","author":"J Khouri","year":"2019","unstructured":"Khouri J, Samaras C, Valent J, Mejia Garcia A, Faiman B, Mathur S, et al. Monoclonal gammopathy of undetermined significance: a primary care guide. Cleve Clin J Med. 2019;86:39\u201346.","journal-title":"Cleve Clin J Med"},{"key":"569_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","volume":"131","author":"RS Go","year":"2018","unstructured":"Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018;131:163\u201373.","journal-title":"Blood"},{"key":"569_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3324\/haematol.2013.100552","volume":"99","author":"NWCJ van de Donk","year":"2014","unstructured":"van de Donk NWCJ, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99:984\u201396.","journal-title":"Haematologica"},{"key":"569_CR22","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1309\/AJCP25IHYLEWCAHJ","volume":"140","author":"MP McTaggart","year":"2013","unstructured":"McTaggart MP, Lindsay J, Kearney EM. Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients. Am J Clin Pathol. 2013;140:890\u20137.","journal-title":"Am J Clin Pathol"},{"key":"569_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1365-2141.2008.07308.x","volume":"143","author":"P Vermeersch","year":"2008","unstructured":"Vermeersch P, Van Hoovels L, Delforge M, et al. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol. 2008;143:496\u2013502.","journal-title":"Br J Haematol"},{"key":"569_CR24","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","volume":"55","author":"JA Katzmann","year":"2009","unstructured":"Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55:1517\u201322.","journal-title":"Clin Chem"},{"key":"569_CR25","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812\u20137.","journal-title":"Blood"},{"key":"569_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u20139.","journal-title":"N Engl J Med"},{"key":"569_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","volume":"123","author":"I Turesson","year":"2014","unstructured":"Turesson I, Kovalchik SA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338\u201345.","journal-title":"Blood"},{"key":"569_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2141.1992.tb08245.x","volume":"81","author":"J Blade","year":"1992","unstructured":"Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol. 1992;81:391\u20134.","journal-title":"Br J Haematol"},{"key":"569_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/leu.2012.189","volume":"27","author":"JA Katzmann","year":"2013","unstructured":"Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd, et al. Suppression of uninvolved immunoglobulins defined by heavy\/light chain pair suppression is a risk factor for progression of MGUS. Leukemia. 2013;27:208\u201312.","journal-title":"Leukemia"},{"key":"569_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.mayocp.2012.03.009","volume":"87","author":"A Dispenzieri","year":"2012","unstructured":"Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc. 2012;87:517\u201323.","journal-title":"Mayo Clin Proc"},{"key":"569_CR31","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona E, Vidriales M-B, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586\u201392.","journal-title":"Blood"},{"key":"569_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","volume":"123","author":"MV Dhodapkar","year":"2014","unstructured":"Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123:78\u201385.","journal-title":"Blood"},{"key":"569_CR33","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","volume":"102","author":"A Mikulasova","year":"2017","unstructured":"Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, et al. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017;102:1617\u201325.","journal-title":"Haematologica"},{"key":"569_CR34","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41375-018-0030-3","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32:1811\u20135.","journal-title":"Leukemia"},{"key":"569_CR35","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","volume":"102","author":"M Varettoni","year":"2017","unstructured":"Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, et al. Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102:2077\u201385.","journal-title":"Haematologica"},{"key":"569_CR36","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","volume":"121","author":"L Xu","year":"2013","unstructured":"Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121:2051\u20138.","journal-title":"Blood"},{"key":"569_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1371\/journal.pone.0221941","volume":"14","author":"A Nakamura","year":"2019","unstructured":"Nakamura A, Ohwada C, Takeuchi M, et al. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenstr\u00f6m\u2019s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS ONE. 2019;14:4. https:\/\/doi.org\/10.1371\/journal.pone.0221941.","journal-title":"PLoS ONE"},{"key":"569_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bjh.16085","volume":"187","author":"P Kapoor","year":"2019","unstructured":"Kapoor P. The MYD88L265P conundrum in IgM monoclonal gammopathy of undetermined significance. Br J Haematol. 2019;187:413\u20135.","journal-title":"Br J Haematol"},{"key":"569_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bjh.16086","volume":"187","author":"M Varettoni","year":"2019","unstructured":"Varettoni M, Zibellini S, Boveri E, Klersy C, Candido C, Rattotti S, et al. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenstr\u00f6m macroglobulinaemia or other lymphoproliferative disorders. Br J Haematol. 2019;187:441\u20136.","journal-title":"Br J Haematol"},{"key":"569_CR40","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1038\/leu.2012.128","volume":"26","author":"L L\u00f3pez-Corral","year":"2012","unstructured":"L\u00f3pez-Corral L, Sarasquete ME, Be\u00e0 S, et al. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia. 2012;26:2521\u20139.","journal-title":"Leukemia"},{"key":"569_CR41","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28:384\u201390.","journal-title":"Leukemia"},{"key":"569_CR42","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/leu.2014.59","volume":"28","author":"S Zhao","year":"2014","unstructured":"Zhao S, Choi M, Heuck C, Mane S, Barlogie B, Lifton RP, et al. Serial exome analysis of disease progression in premalignant gammopathies. Leukemia. 2014;28:1548\u201352.","journal-title":"Leukemia"},{"key":"569_CR43","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1084\/jem.20052136","volume":"203","author":"A Kukreja","year":"2006","unstructured":"Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med. 2006;203:1859\u201365.","journal-title":"J Exp Med"},{"key":"569_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","volume":"16","author":"D Chauhan","year":"2009","unstructured":"Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16:309\u201323.","journal-title":"Cancer Cell"},{"key":"569_CR45","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/cncr.21746","volume":"106","author":"M P\u00e9rez-Andres","year":"2006","unstructured":"P\u00e9rez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nu\u00f1ez G, Galende J, et al. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic\/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer. 2006;106:1296\u2013305.","journal-title":"Cancer"},{"key":"569_CR46","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","volume":"110","author":"J Liu","year":"2007","unstructured":"Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110:296\u2013304.","journal-title":"Blood"},{"key":"569_CR47","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","volume":"27","author":"H Tamura","year":"2013","unstructured":"Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013;27:464\u201372.","journal-title":"Leukemia"},{"key":"569_CR48","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1080\/10428190701648281","volume":"48","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Rizzoli V. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma. 2007;48:2323\u20139.","journal-title":"Leuk Lymphoma"},{"key":"569_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","volume":"80","author":"E Terpos","year":"2018","unstructured":"Terpos E, Christoulas D, Gavriatopoulou M. Biology and treatment of myeloma related bone disease. Metabolism. 2018;80:80\u201390.","journal-title":"Metabolism"},{"key":"569_CR50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4065\/84.8.685","volume":"84","author":"JP Bida","year":"2009","unstructured":"\u2022\u2022 Bida JP, Kyle RA, Therneau TM, Melton LJ 3rd, Plevak MF, Larson DR, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc. 2009;84:685\u201393. One of the largest population based studies of MGUS.","journal-title":"Mayo Clin Proc"},{"key":"569_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1359\/jbmr.0301212","volume":"19","author":"LJ Melton","year":"2004","unstructured":"Melton LJ, Rajkumar SV, Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res Off J Am Soc Bone Miner Res. 2004;19:25\u201330.","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"569_CR52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","volume":"150","author":"JR Berenson","year":"2010","unstructured":"Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010;150:28\u201338.","journal-title":"Br J Haematol"},{"key":"569_CR53","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","volume":"1","author":"EE Sigurdardottir","year":"2015","unstructured":"Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1:168\u201374.","journal-title":"JAMA Oncol"},{"key":"569_CR54","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.3324\/haematol.2017.179978","volume":"103","author":"RS Go","year":"2018","unstructured":"\u2022 Go RS, Heien HC, Sangaralingham LR, et al. Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA. Haematologica. 2018;103:e123\u20135. Study demonstrating rate of progression from time of diagnosis of MGUS along with demographics of MGUS in the U.S..","journal-title":"Haematologica"},{"key":"569_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:12. https:\/\/doi.org\/10.1038\/s41408-018-0077-4.","journal-title":"Blood Cancer J"},{"key":"569_CR56","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785\u20139.","journal-title":"Blood"},{"key":"569_CR57","doi-asserted-by":"publisher","unstructured":"Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/JCO.19.01740.","DOI":"10.1200\/JCO.19.01740"},{"key":"569_CR58","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(09)70234-7","volume":"10","author":"S Grass","year":"2009","unstructured":"Grass S, Preuss K-D, Ahlgrimm M, Fadle N, Regitz E, Pfoehler C, et al. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. Lancet Oncol. 2009;10:950\u20136.","journal-title":"Lancet Oncol"},{"key":"569_CR59","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1182\/blood-2011-01-331454","volume":"118","author":"S Grass","year":"2011","unstructured":"Grass S, Preuss K-D, Thome S, Weisenburger DD, Witt V, Lynch J, et al. Paraproteins of familial MGUS\/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS\/MM. Blood. 2011;118:635\u20137.","journal-title":"Blood"},{"key":"569_CR60","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"N Leung","year":"2012","unstructured":"\u2022 Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120:4292\u20135. Important paper introducing the concept of monoclonal gammopathy of renal significance.","journal-title":"Blood"},{"key":"569_CR61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","volume":"15","author":"N Leung","year":"2019","unstructured":"Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15:45\u201359.","journal-title":"Nat Rev Nephrol"},{"key":"569_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/jdv.13847","volume":"31","author":"D Lipsker","year":"2017","unstructured":"Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol JEADV. 2017;31:45\u201352.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"569_CR63","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.clml.2016.04.009","volume":"16","author":"LS Higgins","year":"2016","unstructured":"Higgins LS, Go RS, Dingli D, et al. Clinical features and treatment outcomes of patients with necrobiotic xanthogranuloma associated with monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2016;16:447\u201352.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"569_CR64","doi-asserted-by":"publisher","unstructured":"Mah\u00e9vas T, Arnulf B, Bouaziz J-D, et al. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood. 2020;6. https:\/\/doi.org\/10.1182\/blood.2019002300.","DOI":"10.1182\/blood.2019002300"},{"key":"569_CR65","doi-asserted-by":"publisher","unstructured":"Kapoor P, Gonsalves W 2020 Of lions, Shar-Pei and doughnuts: a tale retold. Blood. https:\/\/doi.org\/10.1182\/blood.2019004765.","DOI":"10.1182\/blood.2019004765"},{"key":"569_CR66","doi-asserted-by":"publisher","first-page":"905","DOI":"10.4065\/mcp.2010.0159","volume":"85","author":"P Kapoor","year":"2010","unstructured":"Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, et al. Idiopathic systemic capillary leak syndrome (Clarkson\u2019s disease): the Mayo Clinic experience. Mayo Clin Proc. 2010;85:905\u201312.","journal-title":"Mayo Clin Proc"},{"key":"569_CR67","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","volume":"134","author":"J Pepe","year":"2006","unstructured":"Pepe J, Petrucci MT, Nofroni I, Fassino V, Diacinti D, Romagnoli E, et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:485\u201390.","journal-title":"Br J Haematol"},{"key":"569_CR68","first-page":"99","volume":"4","author":"P Johansen","year":"1985","unstructured":"Johansen P, Leegaard OF. Peripheral neuropathy and paraproteinemia: an immunohistochemical and serologic study. Clin Neuropathol. 1985;4:99\u2013104.","journal-title":"Clin Neuropathol"},{"key":"569_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1749-6632.1971.tb13560.x","volume":"190","author":"T Isobe","year":"1971","unstructured":"Isobe T, Osserman EF. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann N Y Acad Sci. 1971;190:507\u201318.","journal-title":"Ann N Y Acad Sci"},{"key":"569_CR70","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.mayocp.2017.02.003","volume":"92","author":"HM Chaudhry","year":"2017","unstructured":"Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017;92:838\u201350.","journal-title":"Mayo Clin Proc"},{"key":"569_CR71","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","volume":"111","author":"LM Brown","year":"2008","unstructured":"Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111:3388\u201394.","journal-title":"Blood"},{"key":"569_CR72","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jamaoncol.2018.0509","volume":"4","author":"O Landgren","year":"2018","unstructured":"Landgren O, Zeig-Owens R, Giricz O, Goldfarb D, Murata K, Thoren K, et al. Multiple myeloma and its precursor disease among firefighters exposed to the world trade center disaster. JAMA Oncol. 2018;4:821\u20137.","journal-title":"JAMA Oncol"},{"key":"569_CR73","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","volume":"107","author":"O Landgren","year":"2006","unstructured":"Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904\u20136.","journal-title":"Blood"},{"key":"569_CR74","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/leu.2014.34","volume":"28","author":"O Landgren","year":"2014","unstructured":"Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28:1537\u201342.","journal-title":"Leukemia"},{"key":"569_CR75","doi-asserted-by":"publisher","first-page":"19649","DOI":"10.7448\/IAS.17.4.19649","volume":"17","author":"P Genet","year":"2014","unstructured":"Genet P, Sutton L, Chaoui D, et al. Prevalence of monoclonal gammopathy in HIV patients in 2014. J Int AIDS Soc. 2014;17:19649.","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 1","key":"569_CR76","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1007\/978-3-642-77423-2_7","volume":"5","author":"C Chakalarovski","year":"1992","unstructured":"Chakalarovski C, Lang P, Buisson C, et al. Monoclonal immunoglobulins in patients with renal transplants: characterization, evolution and risk factors. Transpl Int Off J Eur Soc Organ Transplant. 1992;5(Suppl 1):S23\u20135.","journal-title":"Transpl Int Off J Eur Soc Organ Transplant"},{"key":"569_CR77","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ajh.24772","volume":"92","author":"P Milani","year":"2017","unstructured":"Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92:772\u20139.","journal-title":"Am J Hematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00569-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-020-00569-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00569-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:43:12Z","timestamp":1722645792000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-020-00569-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,28]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1007\/s11899-020-00569-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,28]]},"assertion":[{"value":"28 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}